Literature DB >> 11177550

Glucose-regulated insulin expression in diabetic rats.

S C Barry1, N Ramesh, D Lejnieks, W T Simonson, L Kemper, A Lernmark , W R Osborne.   

Abstract

Retroviral vectors encoding glucose-responsive promoters driving furin expression may provide an amplified, glucose-regulated secretion of insulin. We constructed LhI*TFSN virus to encode a glucose-regulatable transforming growth factor alpha promoter controlling furin expression with a viral LTR promoter driving constitutive expression of furin-cleavable human proinsulin. Autologous BB rat vascular smooth muscle cells transduced with LhI*TFSN virus and cultured in 1.7 and 16.7 mM glucose secreted 50.7 +/- 3.2 and 136.0 +/- 11.0 microU (mean +/- SD) of insulin per 10(6) cells per day, respectively. After the onset of diabetes spontaneously diabetic congenic DR lyp/lyp BB rats received stomach implants containing 2 x 10(6) LhI*TFSN-transduced primary rat vascular smooth muscle cells. In eight treated rats there was a major reduction in insulin requirement to as low as 25% of pretreatment level for up to 3 months and one rat became insulin free without hypoglycemia. Intraperitoneal glucose tolerance tests (IPGTTs) in diabetic rats receiving control implants did not show the characteristic decline in blood glucose of normal rats after glucose administration. In contrast, diabetic rats receiving LhI*TFSN-transduced cells showed significant clearances of blood glucose. These data suggest clinically significant levels of glucose-regulated insulin delivery from implanted vascular smooth muscle cells transduced with LhI*TFSN vector.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177550     DOI: 10.1089/104303401750061195

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

Review 1.  The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue.

Authors:  D Gerace; R Martiniello-Wilks; B A O'Brien; A M Simpson
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

2.  Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats.

Authors:  Daniel Moralejo; Ofer Yanay; Kelly Kernan; Adam Bailey; Ake Lernmark; William Osborne
Journal:  J Biosci Bioeng       Date:  2011-01-08       Impact factor: 2.894

3.  Establishment of an artificial beta-cell line expressing insulin under the control of doxycycline.

Authors:  Xin-Yu Qin; Kun-Tang Shen; Xin Zhang; Zhi-Hong Cheng; Xiang-Ru Xu; Ze-Guang Han
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

4.  Delivery of a therapeutic protein by immune-privileged Sertoli cells.

Authors:  Katelyn Halley; Emily L Dyson; Gurvinder Kaur; Payal Mital; Peter M Uong; Brinda Dass; Sherry N Crowell; Jannette M Dufour
Journal:  Cell Transplant       Date:  2010-08-17       Impact factor: 4.064

5.  Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy.

Authors:  B Ren; B A O'Brien; M A Swan; M E Koina; N Nassif; M Q Wei; A M Simpson
Journal:  Diabetologia       Date:  2007-06-28       Impact factor: 10.122

6.  Bombyxin II Regulates Glucose Absorption and Glycogen Synthesis through the PI3K Signaling Pathway in HepG2 Cells.

Authors:  Hongliang Yang; Hongxia Li; Yang Song; Yujie Sui; Zhenwu Du; Guizhen Zhang
Journal:  Biomed Res Int       Date:  2021-10-18       Impact factor: 3.411

7.  FURIN Promoter Methylation Predicts the Risk of Incident Diabetes: A Prospective Analysis in the Gusu Cohort.

Authors:  Yan He; Yinan Li; Jianan Zhang; Linan Chen; Jing Li; Min Zhang; Qiu Zhang; Ying Lu; Jun Jiang; Xiaolong Zhang; Jianwei Hu; Yi Ding; Mingzhi Zhang; Hao Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-25       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.